Press Releases

Unedited news and product information from vendors.

Emdeon Reports First Quarter 2010 Results
May 06, 2010 (04:05 PM EDT)


-- 7.9% Revenue Growth Over First Quarter 2009

-- 9.3% Increase in Adjusted EBITDA Over First Quarter 2009

NASHVILLE, Tenn., May 6 /PRNewswire-FirstCall/ -- Emdeon Inc. (NYSE: EM), a leading provider of healthcare revenue and payment cycle management solutions, today announced financial results for the first quarter ended March 31, 2010, as summarized below:

($ in millions, except per share amounts)

1Q10


1Q09


% Change

Revenue

$ 237.3


$ 219.9


7.9%

Net Income

$     4.3


$     3.3


29.6%

Net Income per share (diluted)

$   0.02


$   0.02


0.0%

Non-GAAP Adjusted EBITDA

$   62.4


$   57.0


9.3%

Non-GAAP Adjusted Net Income per fully diluted share

$   0.21


$   0.21


0.0%

Non-GAAP fully diluted shares

121.3


106.1





First quarter revenue was $237.3 million, an increase of 7.9%, compared to $219.9 million for the same period in the prior year.  GAAP operating income for the first quarter of 2010 was $30.8 million compared to $28.8 million for the same period last year.  First quarter Adjusted EBITDA grew 9.3% to $62.4 million, or 26.3% of revenue, from Adjusted EBITDA of $57.0 million, or 25.9% of revenue, in the comparable period last year.  

GAAP net income (before noncontrolling interest) for the first quarter of 2010 was $4.3 million compared to GAAP net income of $3.3 million for the same period last year.  GAAP net income per diluted share for the first quarter of 2010 was $0.02 compared to $0.02 in the same period last year.  Adjusted Net Income per fully diluted share for the first quarter of 2010 was $0.21, using a weighted average share count of 121.3 million, compared to $0.21, using a weighted average share count of 106.1 million, for the same period last year.

"Emdeon is off to a good start to the year and delivered solid financial results for the first quarter," said George Lazenby, Emdeon's chief executive officer.  "We are also excited about the growing momentum of our emerging business initiatives, including our provider ePayment solutions and healthcare technology consulting services related to our recent FutureVision and HTMS acquisitions.  Emdeon remains on track to execute on our 2010 financial goals."

At March 31, 2010, Emdeon's cash and cash equivalents totaled $220.4 million.  Total long-term debt under Emdeon's credit facilities was $854.5 million, before unamortized debt discount.

A reconciliation of Emdeon's financial results determined in accordance with U.S. Generally Accepted Accounting Principles (GAAP) to certain non-GAAP financial measures has been provided in the financial statement tables included in this release to supplement its unaudited condensed consolidated financial statements presented on a GAAP basis.  An explanation of these non-GAAP measures is also included below under the heading "Explanation of Non-GAAP Financial Measures."

Financial Outlook

Emdeon affirmed its outlook for annual revenue, Adjusted EBITDA and Adjusted Net Income per fully diluted share for 2010 as follows:

  • 2010 revenue to be between $1.0 to $1.06 billion  
  • 2010 Adjusted EBITDA to be between $266 to $278 million
  • 2010 Adjusted Net Income per fully diluted share to be between $0.90 to $0.94 using a weighted average share count of 122.4 million

Notice of Conference Call and Webcast

Emdeon will conduct a conference call/webcast for investors and institutional analysts on Thursday, May 6, 2010 at 5:00 pm Eastern Time/4:00 pm Central Time to discuss Emdeon's financial results.  

To access Emdeon's live conference call and webcast, dial 866-783-2140 (857-350-1599 for international calls) using conference code 75889855 or visit the Investors section of Emdeon's website:  www.emdeon.com.  Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software to access the webcast.  For those unable to listen to the live broadcast, a conference call replay will be available for one week following the conference call by calling 888-286-8010 (617-801-6888 for international calls) using conference code 83532925.  A webcast replay will also be archived on Emdeon's website for at least 30 days following the conference call.

About Emdeon

Emdeon is a leading provider of revenue and payment cycle management solutions, connecting payers, providers and patients in the U.S. healthcare system. Emdeon's product and service offerings integrate and automate key business and administrative functions of its payer and provider customers throughout the patient encounter. Through the use of Emdeon's comprehensive suite of products and services, which are designed to easily integrate with existing technology infrastructures, customers are able to improve efficiency, reduce costs, increase cash flow and more efficiently manage the complex revenue and payment cycle process. For more information, visit www.emdeon.com.

Forward-Looking Statements

Statements made in this press release that express Emdeon's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements, which Emdeon intends to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.  These statements often include words such as "may," "will," "should," "believe," "expect," "anticipate," "intend," "plan," "estimate" or similar expressions. Forward-looking statements may include information concerning Emdeon's possible or assumed future results of operations, including descriptions of Emdeon's revenues, profitability, outlook and overall business strategy.  You should not place undue reliance on these statements because they are subject to numerous uncertainties and factors relating to Emdeon's operations and business environment, all of which are difficult to predict and many of which are beyond Emdeon's control.  Although Emdeon believes that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect Emdeon's actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements, including but not limited to:  effects of competition, including competition from entities that are customers for certain of Emdeon's products and services; Emdeon's ability to maintain relationships with its customers and channel partners; Emdeon's ability to effectively cross-sell its products and services to existing customers and to continue to generate revenue and maintain profitability by developing and successfully deploying new or updated products and services; pricing pressures on Emdeon's products and services; the anticipated benefits from acquisitions not being fully realized or not being realized within the expected time frames; and general economic, business or regulatory conditions affecting the healthcare information technology and services industries; as well as the other risks discussed in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections and elsewhere in Emdeon's Annual Report on Form 10-K for the year ended December 31, 2009, as well as Emdeon's periodic and other reports, filed with the Securities and Exchange Commission.

You should keep in mind that any forward-looking statement made by Emdeon herein, or elsewhere, speaks only as of the date on which made. Emdeon expressly disclaims any intent, obligation or undertaking to update or revise any forward-looking statements made herein to reflect any change in Emdeon's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Emdeon Inc.

Condensed Consolidated Statements of Operations

(unaudited and amounts in thousands, except share and per share amounts)


For the Three Months


Ended March 31,


2010


2009



Revenue

$   237,279


$   219,885

Costs and expenses:




  Cost of operations (exclusive of depreciation and amortization below)

143,986


134,739

  Development and engineering

8,554


7,075

  Sales, marketing, general and administrative

26,119


24,160

  Depreciation and amortization

27,775


25,098

Operating income

30,845


28,813

Interest income

(3)


(21)

Interest expense

15,665


17,942

Other

290


-

Income before income tax provision

14,893


10,892

Income tax provision

10,630


7,602

Net income

4,263


3,290

Net income attributable to noncontrolling interest

2,374


2,072

Net income attributable to Emdeon Inc.

$       1,889


$       1,218

Net income per share Class A common stock:




  Basic

$         0.02


$         0.02

  Diluted

$         0.02


$         0.02

Weighted average common shares outstanding:




  Basic

90,461,968


77,413,610

  Diluted

90,468,057


77,413,610



Emdeon Inc.

Condensed Consolidated Balance Sheets

(unaudited and amounts in thousands, except share amounts)



March 31,


December 31,


2010


2009

Assets




Current assets:




Cash and cash equivalents

$   220,418


$   211,999

Accounts receivable, net of allowance for doubtful accounts of $4,543 and $4,433 at March 31, 2010 and December 31, 2009, respectively

152,646


151,022

Deferred income tax assets

4,445


4,924

Prepaid expenses and other current assets

15,146


16,632

Total current assets

392,655


384,577

Property and equipment, net

175,231


152,091

Goodwill

730,819


703,027

Intangible assets, net

979,372


989,280

Other assets, net

1,380


1,451

Total assets

$2,279,457


$2,230,426

Liabilities and equity




Current liabilities:




Accounts payable

$       8,677


$       9,910

Accrued expenses

81,956


72,493

Deferred revenues

12,167


12,153

Current portion of long-term debt

10,153


9,972

Total current liabilities

112,953


104,528

Long-term debt, excluding current portion

831,726


830,710

Deferred income tax liabilities

150,502


145,914

Tax receivable agreement obligations to related parties

140,704


142,044

Other long-term liabilities

50,725


27,361

Commitments and contingencies




Equity:




Preferred stock (par value, $0.00001), 25,000,000 shares authorized and 0 shares issued and outstanding

-


-

Class A common stock (par value, $0.00001),  400,000,000 shares authorized and 90,618,894 and 90,423,941 shares outstanding at March 31, 2010 and December 31, 2009, respectively

1


1

Class B common stock, exchangeable (par value, $0.00001), 52,000,000 shares authorized and 24,689,142 and 24,752,955 shares outstanding at March 31, 2010 and December 31, 2009, respectively

-


-

Additional paid-in capital

736,838


730,941

Accumulated other comprehensive loss

(9,334)


(11,198)

Retained earnings

35,593


33,704

Emdeon Inc. equity

763,098


753,448

Noncontrolling interest

229,749


226,421

Total equity

992,847


979,869

Total liabilities and equity

$2,279,457


$2,230,426



Emdeon Inc.

Condensed Consolidated Statements of Cash Flows

(unaudited and amounts in thousands)


For the Three Months


Ended March 31,


2010


2009

Operating activities




Net income

$    4,263


$  3,290

Adjustments to reconcile net income to net cash provided by operating activities:




Depreciation and amortization

27,775


25,098

Equity compensation expense

3,675


2,576

Deferred income tax expense

4,666


2,659

Amortization of debt discount and issuance costs

3,135


2,791

Amortization of discontinued cash flow hedge from other comprehensive loss

1,453


1,972

Other

571


104

Changes in operating assets and liabilities:




Accounts receivable

3,347


(1,216)

Prepaid expenses and other

1,646


6,531

Accounts payable

(2,434)


2,429

Accrued expenses and other liabilities

3,173


(5,915)

Deferred revenues

14


1,343

Tax receivable agreement obligations to related parties

(1,480)


-

Net cash provided by operating activities

49,804


41,662

Investing activities




Purchases of property and equipment

(12,949)


(7,055)

Payments for acquisitions, net of cash acquired

(26,444)


-

Net cash used in investing activities

(39,393)


(7,055)

Financing activities




Debt principal payments

(1,888)


(17,888)

Payments on revolver

-


(10,000)

Other

(104)


158

Net cash used in financing activities

(1,992)


(27,730)

Net increase in cash and cash equivalents

8,419


6,877

Cash and cash equivalents at beginning of period

211,999


71,478

Cash and cash equivalents at end of period

$220,418


$78,355



Segment Information

(unaudited and amounts in thousands)



For the Three Months Ended March 31, 2010






Corporate &




Payer

Provider

Pharmacy

Eliminations

Consolidated

Revenue from external customers







Claims management


$45,476

$        -

$      -

$          -

$45,476

Payment services


56,820

-

-

-

56,820

Patient statements


-

66,676

-

-

66,676

Revenue cycle management


-

40,674

-

-

40,674

Dental


-

7,937

-

-

7,937

Pharmacy services


-

-

19,696

-

19,696

Inter-segment revenue


873

87

-

(960)

-

Net revenue


103,169

115,374

19,696

(960)

237,279

Costs and expenses:







Cost of operations


66,817

71,372

6,725

(928)

143,986

Development and engineering


3,015

3,824

1,715

-

8,554

Sales, marketing, general and administrative


6,873

6,816

1,558

10,872

26,119

Segment contribution (1)


$26,464

$33,362

$9,698

$(10,904)

58,620

Depreciation and amortization






27,775

Interest income






(3)

Interest expense






15,665

Other loss






290

Income before income tax provision






$14,893





For the Three Months Ended March 31, 2009






Corporate &




Payer

Provider

Pharmacy

Eliminations

Consolidated

Revenue from external customers







Claims management


$45,112

$        -

$      -

$        -

$45,112

Payment services


50,346

-

-

-

50,346

Patient statements


-

68,672

-

-

68,672

Revenue cycle management


-

37,746

-

-

37,746

Dental


-

7,760

-

-

7,760

Pharmacy services


-

-

10,249

-

10,249

Inter-segment revenue


70

464

-

(534)

-

Net revenue


95,528

114,642

10,249

(534)

219,885

Costs and expenses:







Cost of operations


59,876

73,434

1,849

(420)

134,739

Development and engineering


2,632

3,422

1,021

-

7,075

Sales, marketing, general and administrative


5,854

7,492

978

9,836

24,160

Segment contribution (1)


$27,166

$30,294

$6,401

$(9,950)

53,911

Depreciation and amortization






25,098

Interest income






(21)

Interest expense






17,942

Income before income tax provision






$10,892















(1) Segment contribution has been reduced by equity-based compensation expense of $3,675 and $2,576 for the three months ended March 31, 2010 and 2009, respectively. Segment contribution without such equity-based compensation expense would have been $62,295 and $56,487 for the three months ended March 31, 2010 and 2009, respectively.



Explanation of Non-GAAP Financial Measures

Emdeon's management team believes that in order to properly understand Emdeon's short-term and long-term financial trends, investors may wish to consider the impact of certain non-cash or non-operating items, when used as a supplement to financial performance measures prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP).  These items result from facts and circumstances that vary in frequency and/or impact continuing operations.  In addition, management uses results of operations before such excluded items to evaluate the operational performance of Emdeon as a basis for strategic planning and, in the case of Adjusted EBITDA, as a performance evaluation metric in determining achievement of certain executive and management incentive compensation programs.  Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.  In addition to the description provided below, reconciliations of GAAP to non-GAAP results are provided in the financial statement tables included in this release.

In this release, Emdeon defines Adjusted EBITDA as EBITDA (which is defined as net income  before net interest expense, income tax provision (benefit) and depreciation and amortization), plus certain other non-cash or non-operating items (collectively, "EBITDA Adjustments").

In this release, Emdeon defines Adjusted Net Income as the sum of (i) GAAP net income, (ii) EBITDA Adjustments, (iii) non-cash interest expense and (iv) depreciation and amortization expense resulting from adjustments of assets to fair value in connection with acquisition accounting, less income taxes computed based on a normalized income tax rate. Emdeon defines Adjusted Net Income per fully diluted share as the quotient of Adjusted Net Income and weighted average shares outstanding, assuming all potentially dilutive securities are fully dilutive and outstanding shares from their date of grant or issuance.

To properly evaluate Emdeon's business, Emdeon encourages investors to review the GAAP financial information included in this release, and not rely on any single financial measure to evaluate Emdeon's business.  Emdeon also strongly encourages investors to review the reconciliation of GAAP net income and GAAP net income per diluted share to the applicable non-GAAP measures of Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income per fully diluted share.  These non-GAAP measures, as Emdeon defines them, may not be similar to non-GAAP measures used by other companies.

Management uses Adjusted EBITDA and Adjusted Net Income per fully diluted share to facilitate a comparison of Emdeon's operating performance on a consistent basis from period to period that, when viewed in combination with Emdeon's GAAP results, management believes provides a more complete understanding of factors and trends affecting Emdeon's business than GAAP measures alone. Management believes these non-GAAP measures assist Emdeon's board of directors, management, lenders and investors in comparing Emdeon's operating performance on a consistent basis because they remove where applicable, the impact of Emdeon's capital and organizational structure, asset base, acquisition accounting, non-cash charges and non-operating items from Emdeon's operations.

Emdeon also presents Adjusted EBITDA and Adjusted Net Income per fully diluted share on a forward-looking basis as part of its Financial Outlook for 2010.  Emdeon is unable to present a quantitative reconciliation of these forward-looking non-GAAP financial measures to the most directly comparable forward-looking GAAP financial measures because management cannot predict, with sufficient reliability, contingent payments relating to past and possible future acquisitions, changes in the fair value of Emdeon's interest rate swap agreement and the effect on income taxes of these and other items attributable to Emdeon's organizational structure, which are difficult to estimate and  primarily dependent on future events.  

Emdeon Inc.

Reconciliation of GAAP Net Income to Adjusted EBITDA

(unaudited and amounts in thousands)



For the Three Months



Ended March 31,



2010


2009






Net income


$   4,263


$   3,290

Interest expense, net


15,662


17,921

Income tax provision


10,630


7,602

Depreciation and amortization


27,775


25,098

EBITDA


58,330


53,911






 Equity-based compensation


3,675


2,576

 Purchase accounting adjustments


176


473

 Facilities consolidation costs


430


85

 Acquisition and divestiture related costs


939


-

 Tax receivable agreements change in estimate


(1,480)


-

 Non-operating loss


290


-

 EBITDA Adjustments


4,030


3,134






Adjusted EBITDA


$ 62,360


$ 57,045



Emdeon Inc.

Reconciliation of GAAP Net Income to Adjusted Net Income

(unaudited and amounts in thousands)



For the Three Months



Ended March 31,



2010


2009






Net income


$   4,263


$   3,290

Income tax provision


10,630


7,602

EBITDA Adjustments


4,030


3,134

Non-cash interest expense


4,588


4,763

Depreciation and amortization resulting from acquisition method adjustments


19,176


18,766






Adjusted net income before income taxes


42,687


37,555

Normalized income tax provision


16,861


14,834






Adjusted Net Income


$ 25,826


$ 22,721



Emdeon Inc.

Reconciliation of Diluted Net Income Per Diluted Share of Class A Common Stock to

Adjusted Net Income Per Fully Diluted Share(1)

(unaudited)



For the Three Months



Ended March 31,



2010


2009

Diluted net income per share Class A common stock


$ 0.02


$ 0.02

Impact of assuming full dilution of all outstanding equity instruments for the period


0.01


0.01

Adjustments on a per share basis:





Income tax provision


0.09


0.07

EBITDA Adjustments


0.03


0.03

Non-cash interest expense


0.04


0.04

Depreciation and amortization resulting from acquisition method adjustments


0.16


0.18






Adjusted net income before income taxes


0.35


0.35

Normalized income tax provision


0.14


0.14

Adjusted Net Income per fully diluted share


$ 0.21


$ 0.21



(1) The calculation of Adjusted Net Income per fully diluted share assumes the following equity-based instruments were fully converted into Class A common stock on their date of issuance:




(shares in thousands)



For the Three Months



Ended March 31,

Weighted average of:


2010


2009

Class A shares outstanding


90,462


77,414

Class B shares outstanding


24,725


24,749

Restricted stock units outstanding


572


924

Options to purchase Class A shares outstanding


5,536


3,060

Shares assumed in Adjusted Net Income per fully diluted share calculation


121,295


106,147



SOURCE Emdeon Inc.